MainMeetings, whether face-to-face or via telephone, with the Investigational New Drug (IND) sponsors and New Drug Application (NDA) applicants facilitate communication with industry to help ensure appropriate product development and address product quality issues. ONDQA participates in many industry meetings. Some, but not all, of these meetings are focused on chemistry, manufacturing, and controls or drug product quality topics and are led by ONDQA. This measure includes the number of meetings held with IND sponsor and NDA applicants for the month. This measure does not include industry meetings ONDQA participated in but are led by other CDER divisions (e.g., Office of New Drugs) or meetings that were scheduled for the month and later canceled. <br>This measure has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research. </b> (1) Does not include industry meetings ONDQA participated in but managed by other CDER divisions.Number

FY 2010 Total: 45

Oct 20090Nov 20090Dec 20094Jan 20102Feb 20103Mar 201010Apr 20106May 20102Jun 20104Jul 201010Aug 20100Sep 20104

FY 2011 Total: 48

Oct 20102Nov 20103Dec 20103Jan 20113Feb 20117Mar 20116Apr 20115May 201113Jun 20113Jul 20110Aug 20111Sep 20112

FY 2012 YTD: 13

Oct 20112Nov 20113Dec 20118Jan 2012Feb 2012Mar 2012Apr 2012May 2012Jun 2012Jul 2012Aug 2012Sep 2012http://www.fda.gov/AboutFDA/Transparency/track/ucm206444.htmFDA-TRACK CDER Dashboard